Foamix Pharmaceuticals Ltd. is a specialty pharmaceutical company that focuses on developing and selling foam-based products for the treatment of various skin conditions, including acne and impetigo. Their lead product candidates, FMX101 and FMX102, have completed Phase II clinical trials and show promise in treating moderate-to-severe acne and methicillin-resistant staphylococcus aureus-caused impetigo, respectively. The company operates in the United States, Germany, and Israel.
Foamix Pharmaceuticals Ltd's ticker is FOMX
The company's shares trade on the NASDAQ stock exchange
They are based in Rehovot, Israel
There are 11-50 employees working at Foamix Pharmaceuticals Ltd
It is http://www.foamix.co.il/
Foamix Pharmaceuticals Ltd is in the Healthcare sector
Foamix Pharmaceuticals Ltd is in the Biotechnology industry
The following five companies are Foamix Pharmaceuticals Ltd's industry peers: